Table 5 −.
Multiple subgroup analyses for relative detection rate of clinically significant prostate cancer
| Variable | Stratification | No. of studies | Relative detection rate (95% CI) | p valuea |
|---|---|---|---|---|
| Study design | Multicenter | 1 | 1.4608 (1.1218, 1.9023) | 0.99 |
| Single center | 8 | 1.4548 (1.0307, 2.0535) | ||
| Clinical setting | Biopsy naïve | 7 | 1.4239 (1.0241, 1.9797) | 0.68 |
| Prior negative biopsy | 2 | 1.6038 (1.0137, 2.5374) | ||
| Definition of csPCa | GS ≥7 (3 + 4) | 3 | 1.5637 (0.9921, 2.4647) | 0.60 |
| GS ≥7 (4 + 3) | 1 | 1.9231 (1.0521, 3.5151) | ||
| GS ≥7 (3 + 4) + core-related informationb | 5 | 1.3210 (0.8608, 2.0273) | ||
| MRI magnet strength | 3 Tesla | 6 | 1.3994 (1.0022, 1.9542) | 0.7654 |
| 1.5 Tesla | 3 | 1.5756 (0.7797, 3.1839) | ||
| Endorectal coil | Used | 4 | 1.9547 (1.7479, 2.1860) | 0.03 |
| Not used | 4 | 1.2707 (0.8842, 1.8260) | ||
| MRI interpretation | Institutional scale | 3 | 1.7710 (0.9484, 3.3069) | 0.79 |
| PI-RADS version 1 | 4 | 1.3460 (0.7945, 2.2803) | ||
| PI-RADS version 2 | 2 | 1.4332 (1.1191, 1.8354) | ||
| Prevalence of MRI (+) patients | >0.71c | 4 | 1.4998 (0.9757, 2.3054) | 0.62 |
| <0.71 | 4 | 1.5904 (1.1742, 2.1542) | ||
| Concurrent SBx in MRI-stratified pathway | MRI-TBx only pathway | 2 | 1.8162 (1.1085, 2.9760) | 0.35 |
| Combined pathway | 7 | 1.3484 (0.9178, 1.9810) | ||
| Navigation | Cognitive fusion | 5 | 1.4363 (0.8668, 2.3798) | 0.59 |
| MRI-TRUS software registration | 3 | 1.6869 (1.2438, 2.2879) |
CI = confidence interval; csPCa = clinically significant prostate cancer; GS = Gleason score; MRI = magnetic resonance imaging; PI-RADS = Prostate Imaging Reporting and Data System; SBx = systematic biopsy; TBx = targeted biopsy; TRUS = transrectal ultrasound.
a
p value for comparing between subgroups.
b
Maximum cancer core length, percentage of core length involved, and/or number of positive cores.
c
Median of studies.